The developers of Terminal-Bench, a benchmark suite for evaluating the performance of autonomous AI agents on real-world ...
Immuthera, operating in the United States, is a wholly owned subsidiary of PolTREG S.A. a leader in innovative immune therapies with focus on regulatory T cell technologies. In addition, Dr. Bot will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback